|
|||||
|
|
Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro |
|
| Authors: | Jinping QiaoChenxin Gu Weihu ShangJinglei Du Wei YinMeilin Zhu Wei WangMei Han Weidong Lu |
| Affiliation: | a Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, PR China b Osher Research Center, Harvard Medical School, Boston, MA 02215, USA c College of Nature Resources and Technology, Beijing Normal University, Beijing 100875, PR China |
| Abstract: | Tea drinking is widely practiced in the world and has recently increased among cancer patients. However, the effects of concurrent consumption of tea on the bioavailability and the net therapeutic potential of co-administered chemical drugs are not clear. In this study, the effects of green tea on the pharmacokinetics of 5-fluorouracil (5-FU) in rats and the pharmacodynamics in human cell lines in vitro were studied. The pharmacokinetic experiment indicated that there was an approximately 151% increase in the maximum plasma concentration (Cmax) and an approximately 425% increase in the area under the plasma concentration curve (AUC) of 5-FU in the green tea-treated group compared with the control group. Green tea consumption increased the plasma concentration of 5-FU. In addition, the pharmacodynamics experiment showed that at the moderate dose level (equivalent to <6 cups daily in human), neither fresh green tea extract nor (−)-epigallocatechin-3-gallate (EGCG) showed significant additive effects on the cytotoxicity of 5-FU in human cell lines. The results showed that it is crucial to perform therapeutic drug monitoring (TDM) when the cancer patients have a habit of drinking green tea. |
| Keywords: | 5-FU, 5-fluorouracil AUC, the area under the curve Cmax, the maximum concentration CV, coefficients of variation EC, (&minus )-epicatechin ECG, (&minus )-epicatechin-3-gallate EGC, (&minus )-epigallocatechin EGCG, (&minus )-epigallocatechin-3-gallate HPLC, high performance liquid chromatography LOQ, the limit of quantification t1/2(ka), the absorption half-life t1/2(ke), the elimination half-life Tmax, the time to reach the maximum concentration TDM, therapeutic drug monitoring |
| 本文献已被 ScienceDirect 等数据库收录！ | |